| 1 |
Alexandraki KI, Angelousi A, Chatzellis E, Chrisoulidou A, Kalogeris N, Kanakis G, Savvidis C, Vassiliadi D, Spyroglou A, Kostopoulos G, Markussis V, Toulis K, Tsagarakis S, Kaltsas GA. The Role of Somatostatin Analogues in the Control of Diarrhea and Flushing as Markers of Carcinoid Syndrome: A Systematic Review and Meta-Analysis. J Pers Med 2023;13. [PMID: 36836538 DOI: 10.3390/jpm13020304] [Reference Citation Analysis]
|
| 2 |
Chen L, Jumai N, He Q, Liu M, Lin Y, Luo Y, Wang Y, Chen MH, Zeng Z, Zhang X, Zhang N. The role of quantitative tumor burden based on [(68) Ga]Ga-DOTA-NOC PET/CT in well-differentiated neuroendocrine tumors: beyond prognosis. Eur J Nucl Med Mol Imaging 2023;50:525-34. [PMID: 36181533 DOI: 10.1007/s00259-022-05971-x] [Reference Citation Analysis]
|
| 3 |
Ilovayskaya IA. Octreotide in the treatment of acromegaly – the possibilities of high-dose therapy. Medicinskij sovet 2022. [DOI: 10.21518/2079-701x-2022-16-10-148-152] [Reference Citation Analysis]
|
| 4 |
Magi L, Rinzivillo M, Panzuto F. What Gastroenterologists Should Know about Carcinoid Syndrome. Gastroenterology Insights 2022;13:127-38. [DOI: 10.3390/gastroent13010014] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 5 |
Wong TY, Zhang KS, Gandhi RT, Collins ZS, O'Hara R, Wang EA, Vaheesan K, Matsuoka L, Sze DY, Kennedy AS, Brown DB. Long-term outcomes following 90Y Radioembolization of neuroendocrine liver metastases: evaluation of the radiation-emitting SIR-spheres in non-resectable liver tumor (RESiN) registry. BMC Cancer 2022;22:224. [PMID: 35232410 DOI: 10.1186/s12885-022-09302-z] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
|
| 6 |
Subash N, Papali MM, Bahadur KP, Avanthika C, Jhaveri S, Thannir S, Joshi M, Valisekka SS. Recent Advances in the Diagnosis and Management of Carcinoid Syndrome. Dis Mon 2021;:101304. [PMID: 34972546 DOI: 10.1016/j.disamonth.2021.101304] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
|
| 7 |
Тyshchenko АМ, Smachylo RM, Mushenko EV, Ivanenko OV. Carcinoid of small intestine - the cause of gastro-intestinal hemorrhage and acute ileus. KH 2021;88:94-97. [DOI: 10.26779/2522-1396.2021.5-6.94] [Reference Citation Analysis]
|
| 8 |
Rinke A, Auernhammer CJ, Bodei L, Kidd M, Krug S, Lawlor R, Marinoni I, Perren A, Scarpa A, Sorbye H, Pavel ME, Weber MM, Modlin I, Gress TM. Treatment of advanced gastroenteropancreatic neuroendocrine neoplasia, are we on the way to personalised medicine? Gut 2021;70:1768-81. [PMID: 33692095 DOI: 10.1136/gutjnl-2020-321300] [Cited by in Crossref: 16] [Cited by in F6Publishing: 15] [Article Influence: 8.0] [Reference Citation Analysis]
|
| 9 |
Chandrasekharan C. Medical Management of Gastroenteropancreatic Neuroendocrine Tumors. Surg Oncol Clin N Am 2020;29:293-316. [PMID: 32151362 DOI: 10.1016/j.soc.2019.11.004] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
|
| 10 |
Kristiansson A, Örbom A, Vilhelmsson Timmermand O, Ahlstedt J, Strand SE, Åkerström B. Kidney Protection with the Radical Scavenger α1-Microglobulin (A1M) during Peptide Receptor Radionuclide and Radioligand Therapy. Antioxidants (Basel) 2021;10:1271. [PMID: 34439519 DOI: 10.3390/antiox10081271] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 11 |
Dawod M, Gordoa TA, Cives M, De Mestier L, Crona J, Spada F, Oberg K, Pavel M, Lamarca A. Antiproliferative Systemic Therapies for Metastatic Small Bowel Neuroendocrine Tumours. Curr Treat Options Oncol 2021;22:73. [PMID: 34185197 DOI: 10.1007/s11864-021-00863-y] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 2.5] [Reference Citation Analysis]
|
| 12 |
Spada F, Rossi RE, Kara E, Laffi A, Massironi S, Rubino M, Grimaldi F, Bhoori S, Fazio N. Carcinoid Syndrome and Hyperinsulinemic Hypoglycemia Associated with Neuroendocrine Neoplasms: A Critical Review on Clinical and Pharmacological Management. Pharmaceuticals (Basel) 2021;14:539. [PMID: 34199977 DOI: 10.3390/ph14060539] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
|
| 13 |
Panzuto F, Rinzivillo M. Treatment of Intestinal NETs (Including Appendix). Neuroendocrine Neoplasia Management 2021. [DOI: 10.1007/978-3-030-72830-4_15] [Reference Citation Analysis]
|
| 14 |
Özdirik B, Tacke F, Benz F, Amthauer H, Fehrenbach U, Roderburg C, Jann H. A case report of an excellent response to interferon- α in a patient with functional metastasized neuroendocrine tumor refractory to other treatments. Medicine (Baltimore) 2020;99:e20820. [PMID: 32569231 DOI: 10.1097/MD.0000000000020820] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
|
| 15 |
Hofland J, Herrera-Martínez AD, Zandee WT, de Herder WW. Management of carcinoid syndrome: a systematic review and meta-analysis. Endocr Relat Cancer 2019;26:R145-56. [PMID: 30608900 DOI: 10.1530/ERC-18-0495] [Cited by in Crossref: 30] [Cited by in F6Publishing: 32] [Article Influence: 10.0] [Reference Citation Analysis]
|
| 16 |
Bacorn C, Kim E, Borowsky AD, Lin LK. Previously undiagnosed neuroendocrine tumour mimicking breast cancer metastasis to the orbit. BMJ Case Rep 2020;13:e234629. [PMID: 32439746 DOI: 10.1136/bcr-2020-234629] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
|
| 17 |
Pavel M, Öberg K, Falconi M, Krenning EP, Sundin A, Perren A, Berruti A; ESMO Guidelines Committee. Electronic address: clinicalguidelines@esmo.org. Gastroenteropancreatic neuroendocrine neoplasms: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 2020;31:844-60. [PMID: 32272208 DOI: 10.1016/j.annonc.2020.03.304] [Cited by in Crossref: 254] [Cited by in F6Publishing: 279] [Article Influence: 84.7] [Reference Citation Analysis]
|
| 18 |
Ferrer-Gago FJ, Koh LQ. Methods and Approaches for the Solid-Phase Synthesis of Peptide Alcohols. Chempluschem 2020;85:641-52. [PMID: 32237227 DOI: 10.1002/cplu.201900749] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
|
| 19 |
Ferrer-Gago FJ, Koh LQ, Lane DP. Functionalized Resins for the Synthesis of Peptide Alcohols. Chemistry 2020;26:379-83. [PMID: 31609031 DOI: 10.1002/chem.201903965] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 20 |
Chen L, Chen J. Perspective of neo-adjuvant/conversion and adjuvant therapy for pancreatic neuroendocrine tumors. Journal of Pancreatology 2019;2:91-9. [DOI: 10.1097/jp9.0000000000000023] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
|
| 21 |
Saif MW, Parikh R, Ray D, Kaye JA, Kurosky SK, Thomas K, Ramirez RA, Halfdanarson TR, Beveridge TJR, Mirakhur B, Nagar SP, Soares HP. Medical record review of transition to lanreotide following octreotide for neuroendocrine tumors. J Gastrointest Oncol 2019;10:674-87. [PMID: 31392048 DOI: 10.21037/jgo.2019.03.11] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
|
| 22 |
Laughlin B, Scott A, Goyal U. Pathologic Complete Response After Neoadjuvant Chemoradiation in a Patient with Gastric Neuroendocrine Cancer. Cureus 2019;11:e5214. [PMID: 31565618 DOI: 10.7759/cureus.5214] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
|
| 23 |
Perico N, Ruggenenti P, Perna A, Caroli A, Trillini M, Sironi S, Pisani A, Riccio E, Imbriaco M, Dugo M, Morana G, Granata A, Figuera M, Gaspari F, Carrara F, Rubis N, Villa A, Gamba S, Prandini S, Cortinovis M, Remuzzi A, Remuzzi G; ALADIN 2 Study Group. Octreotide-LAR in later-stage autosomal dominant polycystic kidney disease (ALADIN 2): A randomized, double-blind, placebo-controlled, multicenter trial. PLoS Med 2019;16:e1002777. [PMID: 30951521 DOI: 10.1371/journal.pmed.1002777] [Cited by in Crossref: 30] [Cited by in F6Publishing: 27] [Article Influence: 7.5] [Reference Citation Analysis]
|
| 24 |
Hofland J, Herrera-martínez AD, Zandee WT, de Herder WW. Management of carcinoid syndrome: a systematic review and meta-analysis. Endocrine-Related Cancer 2019;26:R145-56. [DOI: 10.1530/erc-18-0495] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
|
| 25 |
Ito T, Lee L, Jensen RT. Carcinoid-syndrome: recent advances, current status and controversies. Curr Opin Endocrinol Diabetes Obes 2018;25:22-35. [PMID: 29120923 DOI: 10.1097/MED.0000000000000376] [Cited by in Crossref: 58] [Cited by in F6Publishing: 65] [Article Influence: 14.5] [Reference Citation Analysis]
|
| 26 |
Mungamuri SK, Pasupulati AK, Mavuduru VA. Immunotherapy for Diabetogenic Pancreatitis and Pancreatic Cancer: An Update. Exploring Pancreatic Metabolism and Malignancy 2019. [DOI: 10.1007/978-981-32-9393-9_13] [Reference Citation Analysis]
|
| 27 |
Fisher GA. Gastroenteropancreatic Neuroendocrine Tumors. Textbook of Gastrointestinal Oncology 2019. [DOI: 10.1007/978-3-030-18890-0_16] [Reference Citation Analysis]
|
| 28 |
Papanagnou P, Papadopoulos GE, Stivarou T, Pappas A. Toward fully exploiting the therapeutic potential of marketed pharmaceuticals: the use of octreotide and chloroquine in oncology. Onco Targets Ther 2019;12:319-39. [PMID: 30643430 DOI: 10.2147/OTT.S182685] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.6] [Reference Citation Analysis]
|
| 29 |
Lesén E, Björstad Å, Björholt I, Marlow T, Bollano E, Feuilly M, Marteau F, Welin S, Elf AK, Johanson V. Real-world treatment patterns, resource use and costs of treating uncontrolled carcinoid syndrome and carcinoid heart disease: a retrospective Swedish study. Scand J Gastroenterol 2018;53:1509-18. [PMID: 30449217 DOI: 10.1080/00365521.2018.1531653] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 1.2] [Reference Citation Analysis]
|
| 30 |
Cella D, Beaumont JL, Hudgens S, Marteau F, Feuilly M, Houchard A, Lapuerta P, Ramage J, Pavel M, Hörsch D, Kulke MH. Relationship Between Symptoms and Health-related Quality-of-life Benefits in Patients With Carcinoid Syndrome: Post Hoc Analyses From TELESTAR. Clin Ther 2018;40:2006-2020.e2. [PMID: 30477789 DOI: 10.1016/j.clinthera.2018.10.008] [Cited by in Crossref: 21] [Cited by in F6Publishing: 19] [Article Influence: 4.2] [Reference Citation Analysis]
|
| 31 |
Wu Q, Chen B, Yan G, Yang Z, Xiong L, He J. A systematic review and meta-analysis of gastrointestinal events associated with nonoperative therapies for neuroendocrine tumors. Onco Targets Ther 2018;11:7655-68. [PMID: 30464514 DOI: 10.2147/OTT.S181335] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.2] [Reference Citation Analysis]
|
| 32 |
Räder AFB, Weinmüller M, Reichart F, Schumacher-klinger A, Merzbach S, Gilon C, Hoffman A, Kessler H. Orally Active Peptides: Is There a Magic Bullet? Angew Chem Int Ed 2018;57:14414-38. [DOI: 10.1002/anie.201807298] [Cited by in Crossref: 81] [Cited by in F6Publishing: 78] [Article Influence: 16.2] [Reference Citation Analysis]
|
| 33 |
Räder AFB, Weinmüller M, Reichart F, Schumacher-klinger A, Merzbach S, Gilon C, Hoffman A, Kessler H. Oral aktive Peptide: Gibt es ein Patentrezept? Angew Chem 2018;130:14614-40. [DOI: 10.1002/ange.201807298] [Cited by in Crossref: 13] [Cited by in F6Publishing: 13] [Article Influence: 2.6] [Reference Citation Analysis]
|
| 34 |
Lau SC, Abdel-Rahman O, Cheung WY. Improved survival with higher doses of octreotide long-acting release in gastroenteropancreatic neuroendocrine tumors. Med Oncol 2018;35:123. [PMID: 30078166 DOI: 10.1007/s12032-018-1189-1] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 1.2] [Reference Citation Analysis]
|
| 35 |
Barrows SM, Cai B, Copley-Merriman C, Wright KR, Castro CV, Soufi-Mahjoubi R. Systematic literature review of the antitumor effect of octreotide in neuroendocrine tumors. World J Meta-Anal 2018; 6(2): 9-20 [DOI: 10.13105/wjma.v6.i2.9] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.4] [Reference Citation Analysis]
|
| 36 |
Pusceddu S, Prinzi N, Raimondi A, Corti F, Buzzoni R, Di Bartolomeo M, Seregni E, Maccauro M, Coppa J, Milione M, Mazzaferro V, de Braud F. Entering the third decade of experience with octreotide LAR in neuroendocrine tumors: A review of current knowledge. Tumori 2019;105:113-20. [DOI: 10.1177/0300891618765362] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 1.6] [Reference Citation Analysis]
|
| 37 |
Cuyle PJ, Prenen H. Practical management of toxicities associated with targeted therapies for advanced gastroenteropancreatic neuroendocrine tumors. Ann Gastroenterol. 2018;31:140-150. [PMID: 29507461 DOI: 10.20524/aog.2018.0224] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.4] [Reference Citation Analysis]
|
| 38 |
Auernhammer CJ, Spitzweg C, Angele MK, Boeck S, Grossman A, Nölting S, Ilhan H, Knösel T, Mayerle J, Reincke M, Bartenstein P. Advanced neuroendocrine tumours of the small intestine and pancreas: clinical developments, controversies, and future strategies. Lancet Diabetes Endocrinol 2018;6:404-15. [PMID: 29229497 DOI: 10.1016/S2213-8587(17)30401-1] [Cited by in Crossref: 41] [Cited by in F6Publishing: 44] [Article Influence: 6.8] [Reference Citation Analysis]
|
| 39 |
Cangiano B, Fatti LM, Persani L, Vitale G. Nuovi farmaci a bersaglio molecolare nei tumori neuroendocrini gastroenteropancreatici. L'Endocrinologo 2017;18:280-284. [DOI: 10.1007/s40619-017-0359-2] [Reference Citation Analysis]
|
| 40 |
Faggiano A, Lo Calzo F, Pizza G, Modica R, Colao A. The safety of available treatments options for neuroendocrine tumors. Expert Opin Drug Saf 2017;16:1149-61. [PMID: 28705090 DOI: 10.1080/14740338.2017.1354984] [Cited by in Crossref: 20] [Cited by in F6Publishing: 18] [Article Influence: 3.3] [Reference Citation Analysis]
|
| 41 |
Chan DL, Ferone D, Albertelli M, Pavlakis N, Segelov E, Singh S. Escalated-dose somatostatin analogues for antiproliferative effect in GEPNETS: a systematic review. Endocrine. 2017;57:366-375. [PMID: 28726183 DOI: 10.1007/s12020-017-1360-z] [Cited by in Crossref: 23] [Cited by in F6Publishing: 22] [Article Influence: 3.8] [Reference Citation Analysis]
|
| 42 |
Huynh L, Totev T, Vekeman F, Neary MP, Duh MS, Benson AB. Cost reduction from resolution/improvement of carcinoid syndrome symptoms following treatment with above-standard dose of octreotide LAR. Journal of Medical Economics 2017;20:945-51. [DOI: 10.1080/13696998.2017.1337019] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.8] [Reference Citation Analysis]
|
| 43 |
Albertelli M, Nazzari E, Sciallero S, Grillo F, Morbelli S, De Cian F, Cittadini G, Ambrosetti E, Ciarmiello A, Ferone D; IRCCS Policlinico San Martino, University of Genova Neuroendocrine Tumor Board. Anti-tumoral effects of somatostatin analogs: a lesson from the CLARINET study. J Endocrinol Invest 2017;40:1265-9. [PMID: 28550464 DOI: 10.1007/s40618-017-0692-0] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.7] [Reference Citation Analysis]
|
| 44 |
Machado-Alba JE, Machado-Duque ME. Prescription patterns of long-acting somatostatin analogues. SAGE Open Med 2017;5:2050312117694795. [PMID: 28540043 DOI: 10.1177/2050312117694795] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 0.7] [Reference Citation Analysis]
|
| 45 |
Wang Y, Wang W, Jin K, Fang C, Lin Y, Xue L, Feng S, Zhou Z, Shao C, Chen M, Yu X, Chen J. Somatostatin receptor expression indicates improved prognosis in gastroenteropancreatic neuroendocrine neoplasm, and octreotide long-acting release is effective and safe in Chinese patients with advanced gastroenteropancreatic neuroendocrine tumors. Oncol Lett. 2017;13:1165-1174. [PMID: 28454229 DOI: 10.3892/ol.2017.5591] [Cited by in Crossref: 35] [Cited by in F6Publishing: 38] [Article Influence: 5.8] [Reference Citation Analysis]
|
| 46 |
Ulapane KR, Kopec BM, Moral MEG, Siahaan TJ. Peptides and Drug Delivery. Adv Exp Med Biol 2017;1030:167-84. [PMID: 29081054 DOI: 10.1007/978-3-319-66095-0_8] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 47 |
Pavel M, Becerra C, Grosch K, Cheung W, Hasskarl J, Yao J. Effect of everolimus on the pharmacokinetics of octreotide long-acting repeatable in patients with advanced neuroendocrine tumors: An analysis of the randomized phase III RADIANT-2 trial. Clin Pharmacol Ther 2017;101:462-8. [DOI: 10.1002/cpt.559] [Cited by in Crossref: 8] [Cited by in F6Publishing: 11] [Article Influence: 1.1] [Reference Citation Analysis]
|
| 48 |
Faggiano A, Carratù AC, Guadagno E, Tafuto S, Tatangelo F, Riccardi F, Mocerino C, Palmieri G, Damiano V, Siciliano R, Leo S, Mauro A, Tozzi LF, Battista C, De Rosa G, Colao A. Somatostatin analogues according to Ki67 index in neuroendocrine tumours: an observational retrospective-prospective analysis from real life. Oncotarget 2016;7:5538-47. [PMID: 26701729 DOI: 10.18632/oncotarget.6686] [Cited by in Crossref: 21] [Cited by in F6Publishing: 23] [Article Influence: 3.0] [Reference Citation Analysis]
|
| 49 |
Lamarca A, Barriuso J, McNamara MG, Hubner RA, Valle JW. Telotristat ethyl: a new option for the management of carcinoid syndrome. Expert Opin Pharmacother. 2016;17:2487-2498. [PMID: 27817224 DOI: 10.1080/14656566.2016.1254191] [Cited by in Crossref: 19] [Cited by in F6Publishing: 18] [Article Influence: 2.7] [Reference Citation Analysis]
|
| 50 |
Riechelmann RP, Pereira AA, Rego JF, Costa FP. Refractory carcinoid syndrome: A review of treatment options. Ther Adv Med Oncol. 2017;9:127-137. [PMID: 28203303 DOI: 10.1177/1758834016675803] [Cited by in Crossref: 39] [Cited by in F6Publishing: 43] [Article Influence: 5.6] [Reference Citation Analysis]
|
| 51 |
Massironi S, Conte D, Rossi RE. Somatostatin analogues in functioning gastroenteropancreatic neuroendocrine tumours: literature review, clinical recommendations and schedules. Scand J Gastroenterol 2016;51:513-23. [PMID: 26605828 DOI: 10.3109/00365521.2015.1115117] [Cited by in Crossref: 18] [Cited by in F6Publishing: 19] [Article Influence: 2.6] [Reference Citation Analysis]
|
| 52 |
Pokuri VK, Fong MK, Iyer R. Octreotide and Lanreotide in Gastroenteropancreatic Neuroendocrine Tumors. Curr Oncol Rep 2016;18:7. [PMID: 26743514 DOI: 10.1007/s11912-015-0492-7] [Cited by in Crossref: 26] [Cited by in F6Publishing: 31] [Article Influence: 3.7] [Reference Citation Analysis]
|
| 53 |
Ito T, Lee L, Jensen RT. Treatment of symptomatic neuroendocrine tumor syndromes: recent advances and controversies. Expert Opin Pharmacother. 2016;17:2191-2205. [PMID: 27635672 DOI: 10.1080/14656566.2016.1236916] [Cited by in Crossref: 45] [Cited by in F6Publishing: 32] [Article Influence: 6.4] [Reference Citation Analysis]
|
| 54 |
Dimitriadis GK, Weickert MO, Randeva HS, Kaltsas G, Grossman A. Medical management of secretory syndromes related to gastroenteropancreatic neuroendocrine tumours. Endocr Relat Cancer. 2016;23:R423-R436. [PMID: 27461388 DOI: 10.1530/erc-16-0200] [Cited by in Crossref: 44] [Cited by in F6Publishing: 47] [Article Influence: 6.3] [Reference Citation Analysis]
|
| 55 |
Roviello G, Zanotti L, Venturini S, Bottini A, Generali D. Role of targeted agents in neuroendocrine tumors: Results from a meta-analysis. Cancer Biol Ther 2016;17:883-8. [PMID: 27414404 DOI: 10.1080/15384047.2016.1210735] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 0.6] [Reference Citation Analysis]
|
| 56 |
Mehrvarz Sarshekeh A, Halperin DM, Dasari A. Update on management of midgut neuroendocrine tumors. Int J Endocr Oncol 2016;3:175-89. [PMID: 27347369 DOI: 10.2217/ije-2015-0004] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.6] [Reference Citation Analysis]
|
| 57 |
Shen C, Xu Y, Dasari A, Shih YC, Yao JC. Octreotide LAR Dosage and Survival Among Elderly Patients With Distant-Stage Neuroendocrine Tumors. Oncologist. 2016;21:308-313. [PMID: 26911407 DOI: 10.1634/theoncologist.2015-0381] [Cited by in Crossref: 13] [Cited by in F6Publishing: 14] [Article Influence: 1.9] [Reference Citation Analysis]
|
| 58 |
Rayado GG, Marco MS. Tumores del intestino delgado. Pólipos intestinales. Poliposis familiares. Síndrome carcinoide. Linfomas. Sarcomas intestinales. Medicine - Programa de Formación Médica Continuada Acreditado 2016;12:189-196. [DOI: 10.1016/j.med.2016.02.012] [Reference Citation Analysis]
|
| 59 |
Yang A, Brown J, Mak E. Persistent Diarrhea after Celiac Plexus Block in a Pancreatic Cancer Patient: Case Report and Literature Review. Journal of Palliative Medicine 2016;19:83-6. [DOI: 10.1089/jpm.2015.0117] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 1.1] [Reference Citation Analysis]
|
